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Abstract
Objective: To determine the extent of linezolid and ertapenem penetration into the empyemic fluid using a rabbit 
model of empyema.
Methods: An empyema was created via the intrapleural injection of Escherichia coli bacteria (ATCC 35218) into the 
pleural space of New Zealand white rabbits. After an empyema was verified by thoracocentesis, 24 hours post 
inoculation, linezolid (10 mg/kg) and ertapenem (60 mg/kg) were administered intravenously into 10 and 8 infected 
empyemic rabbits, respectively. Antibiotic levels were determined in samples of pleural fluid and blood serum, 
collected serially at 1, 2, 4, 6 and 8 hours, after administration each of the two antibiotics.
Results: Linezolid as well as ertapenem penetrate well into the empyemic pleural fluid, exhibiting a slower onset and 
decline compared to the corresponding blood serum levels. Equilibration between blood serum and pleural fluid 
compartments seems to occur at 1.5 hours for both linezolid and ertapenem, with peak pleural fluid levels (Cmaxpf of 
2.02 ± 0.73 «mu»g/ml and Cmaxpf of 3.74 ± 1.39 «mu»g/ml, correspondingly) occurring 2 hours post antibiotics 
administration and decreasing very slowly thereafter. The serum concentrations for both antibiotics were significantly 
lower from the corresponding pleural fluid ones during the 8 hours collecting data, with the exception of samples 
collected at the 1st hour (Cmaxserum of 2.1 ± 1.2 «mu»g/ml for linezolid and Cmaxserum of 6.26 ± 2.98 «mu»g/ml for 
ertapenem).
Conclusion: Pleural fluid levels of both antibiotics are inhibitory for common specified pathogens causing empyema.
Introduction
The annual incidence of bacterial pneumonia is estimated
to be 2-4 million in the USA, with approximately 20% of
patients requiring hospitalization [1]. Of these patients
40-60% develop parapneumonic pleural effusions and
pleural empyemas occur in 5-10% [2]. Mortality among
patients with thoracic empyema ranges from 5 to 30% [3]
and if the patients are immunocompromised it can be as
high as 40% [2].
The bacteriology of pleural empyema is related to that
of the pneumonic infection and is usually due to a mix-
ture of anaerobic and aerobic organisms. Streptococci
(Streptococcus pneumoniae), and staphylococci (Staphy-
lococcus aureus) usually dominate gram-positive isolates,
while Escherichia coli, Klebsiella species, Pseudomonas
species, and Haemophilus influenzae are the most com-
mon gram-negative isolates [4]. Anaerobic organisms are
often found in combination with other organisms.
There are several therapeutic options available [5] and
the choice of therapy is usually dictated by the severity of
the disease on presentation and should follow the existing
guidelines for treatment of community or hospital-
acquired pneumonia [2]. The usual initial treatment
remains parenteral antibiotics with chest tube placement
[6]. Therapy needs to be initiated as soon as pleural fluid,
sputum and blood samples have been taken but with the
following in mind: in addition to the specificity of antimi-
crobial agent for the offending microorganism, its distri-
bution within the body is a critical factor in determining
its therapeutic efficacy. If the antimicrobial agent does
not enter the side at which the offending microorganism
resides, bacterial growth will continue despite in vitro
* Correspondence: bouros@med.duth.gr
3 Department of Pneumonology, Medical School, Democritus University of 
Thrace, Alexandroupolis, Greece
Full list of author information is available at the end of the article© 2010 Saroglou et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Saroglou et al. Journal of Inflammation 2010, 7:22
http://www.journal-inflammation.com/content/7/1/22
Page 2 of 8susceptibility of the organism to the drug. In fact, specific
to the treatment of pleural infections, it is important to
obtain sufficient levels of the antibiotics in the pleural
fluid [7]. Second and third generation cephalosporins,
beta-lactam-beta-lactamase inhibitor combinations, flu-
oroquinolones, metronidazole, clindamycin, meropenem,
or aztreonam may be considered [8].
The purpose of the present study was to determine the
pharmacokinetic parameters of linezolid and ertapenem
in the blood and pleural fluid in an experimental rabbit
model of empyema, after intravenous administration. It
was hypothesized that both antibiotics would penetrate
well into the pleural fluid and achieve therapeutic levels
in the pleural fluid of rabbits with empyema.
Materials and methods
Animals
A total of 22 male New Zealand white rabbits (weight
range 2.40-2.70 kg) were used for the study. The animals
were housed in individual cages and allowed food and tap
water ad libitum. Room temperature ranged between 18
and 22°C, relative humidity between 55 and 65% and the
light/dark circle was 6 am/6 pm. The study protocol was
approved by the Veterinary Administration Medical Cen-
tre, Athens, Greece, in conformance to the 160/1991
Council Directive of the EU.
Bacteria preparation
The Escherichia coli strain (ATCC 35218) was grown on
McCongi agar (Becton Dickinson, Sparks, MD, USA) for
24 h at 35°C. Escherichia coli bacteria (in a 5-ml volume
of saline solution) were injected into the right pleural
space.
Empyema induction
The rabbits were anaesthetised with ketamine; 50 mg/kg
i.m. (Ketaset; Fort Dodge Laboratories Inc., Fort Dodge,
IA, USA); atropine, 0.04 mg/kg (Demo SA, Athens,
Greece); and xylazine, 5 mg/kg i.m. (Rompun; Bayer AG,
Leverkusen).
The right chest wall of each rabbit was shaved and then
scrubbed with povidone-iodine and alcohol. The animals
were placed in a supine position on an operating table,
under a heating lamp, and a 0.5-cm medial-to-lateral skin
incision was made over the right anterior chest, using a
scalpel. A specially prepared 16-gauge angiocatheter
(containing additional holes near the tip of the catheter)
was then introduced into the pleural space. After the
placement of the catheter, any air within the pleural space
was aspirated and the catheter was secured s. c. in the
area between the scapulas [9]. The chest tubes were
attached to a Heimlich valve with a three-way stopcock,
in-line between the chest tube and the Heimlich valve.
Turpentine (1 ml) [10] (Riedel de Haen; Sigma-Aldrich
Laborchemikalien, GMBH, Seelze Germany) was admin-
istered into the pleural space of the animals and the chest
tube was then flushed with 1.5 ml of saline solution.
Escherichia coli (ATCC 35218 in a final volume of 5 ml
saline) were injected 24 h later through the cannula into
the pleural cavity of the animals.
Empyema verification
A maximum of 0.5 ml of pleural fluid was removed for
analysis 2, 8, 24, 48, and 72 hours, after bacterial injec-
tion. The pH of the pleural fluid was estimated using a
blood gas machine [11] (Gem premier 3000, model 5700;
Instrumentation laboratory, Lexington, MA, USA), and
the glucose and lactate-D-hydrogenase (LDH) levels,
were estimated using a common microbiological labora-
tory test (the upper limit of LDH in the present study's
laboratory was 460 U/L). An empyema was said to be
present if the pleural fluid (selected appeared grossly
infected, if the glucose levels were < 40 mg/dl and if the
pleural fluid pH was < 7.10 and the LDH was > 1,000 U/L
[12]. Data of rabbits' pleural fluid biochemical analysis are
presented on table 1.
Antibiotic administration
After the presence of an empyema was verified, 10 rabbits
were injected with linezolid, (10 mg/kg) [Zyvoxid 600
mg/vial i.v., Pfizer, Italy], and 8 with ertapenem (60 mg/
kg) [Invanz 1gr/vial i.v., Merck Sharp & Dohme, USA]
through their marginal ear vein over a 15-min period.
Four animals served as controls and were infected with
Escherichia coli but were not treated with any antibiotic.
Pleural fluid and blood specimens
Blood and empyemic pleural fluid specimens were seri-
ally collected 1, 2, 4, 6 and 8 hours, after administration of
each antibiotic, for the estimation of antibiotic levels.
Immediately after the specimens were collected, the
blood and the pleural fluid samples were centrifuged at
3,000 rpm for 15 min. Supernatants were then refriger-
ated at -20°C overnight. Duplicate specimens of blood
and pleural fluid were obtained at each time point. The
means of the duplicate values at each time point were
used for the analysis.
Sample preparation and antibiotic level estimation
Chemicals
Methanol and acetonitrile (Hiper Solv BDH Laboratory
supplies Poole, BH15 1TD, England), water and
orthophosphoric acid 85%, (E. Merck, Darmstadt, Ger-
many) were used for the HPLC analysis.
Preparation of standard curves
Stock solutions of linezolid and ertapenem were prepared
in 100 μg/ml of water and stored at 4°C. Eight point stan-
dard curves for linezolid and ertapenem were prepared at
concentration 0, 0.125, 0.25, 0.5, 1, 2.5, 5 and 10 μg/ml.
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Table 1: Pleural fluid analysis in experimental rabbits model. 24 hours after bacterial inoculation (Escherichia coli).
Animal pH Glucose (mg/dl) LDH (U/L)
Control 1 7.083 17 2025
Control 2 7.099 20 3113
Control 3 7.084 24 1875
Control 4 6.950 18 2296
Ertapenem group
1 6.780 8 3113
2 6.932 11 8307
3 7.036 10 9180
4 6.862 9 3188
5 6.900 6 2070
6 7.160 11 4400
7 7.031 12 2248
8 7.009 18 2902
Linezolid group
1 6.907 10 9180
2 7.080 22 4540
3 7.090 19 2574
4 6.700 9 2877
5 7.100 19 4030
6 7.090 22 4540
7 6.914 13 12500
8 7.100 24 2902
9 7.080 20 2248
10 7.000 22 4400
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linearity greater than 0.999.
Quantification of biological extracts
Blood samples from healthy animals were used as blank
samples. An 8-point calibration curve was prepared for
both drugs. The final concentrations of the fortified sam-
ples were 0, 0.25, 0.5, 1, 2.5, 5, 10 and 25 μg/ml. The cali-
bration curves were linear (r2 = 0.9983, for linezolid and
r2 = 0.9966 for ertapenem). The limit of quantification
(LOQ) were calculated on the basis of signal to noise ratio
10, (S/N = 10) and was determined at 0.125 μg/ml and
0.25 μg/ml for linezolid and ertapenem respectively.
Apparatus
The quantification of the samples was performed by a
reversed-phase HPLC method (on a Spectra Physics
8800, San Jose, California, USA) using a Supelco, 5 μm,
250 mm × 4.6 mm ID column (Discovery C18, 595 North
Harrison Road, USA). The mobile phase for the determi-
nation of linezolid consisted of acetonitrile:water (20:80
v/v) [13] and water:methanol:orthophosphoric acid
(64:35:1 v/v/v) for ertepenem [14]. The elution conditions
were isocratic and the mobile phase flow-rate was set at
1.0 ml/min and 0.8 ml/min for linezolid and ertapenem
respectively. UV absorbance detection at 254 nm (line-
zolid) and 298 nm (ertapenem) was carried out with a uv/
vis detector (Spectra Physics 8450, San Jose, California,
USA) with the range set at 0.01 AUFS. Under these condi-
tions the retention time of linezolid and ertapenem was
13.7 min and 15.7 min respectively.
Extraction procedure for HPLC analysis
The biological sample (100 μl), (blood or pleural empy-
ema) was diluted with 100 μl of acetonitrile (for linezolid)
[15] or 100 μl of methanol (for ertapenem) [14]. The solu-
tion was vortexed for 20 sec and centrifuged for 5 min at
14000 rpm in order to separate the precipitated proteins;
20 μl of the supernatant was injected into the column.
The recovery of linezolid and ertapenem was calculated
at 102.5% and 104.1% respectively by spiked solutions at a
concentration of 0.5, 1, 5, 10 μg/ml.
Necropsy of the rabbits
The antibiotic-free rabbits from the control group died 24
to 48 hours after the inoculation, with fever and diarrhea.
The rabbits in which, ertapenem and linezolid were
infused, were sacrificed via a lethal dose of pentobarbital
i.v. through the marginal ear vein after the collection of
the 8th hour sample.
Statistical analysis
All data were entered into Microsoft Office, Excel, and
analyzed using the statistical program SPSS (13.0 Illinois,
Chicago). Analysis was carried out by means of Student's
t-tests with a p < 0.05 level considered statistically signifi-
cant. The areas under the concentration-time curves
(AUC) were estimated by the trapezoidal rule, while the
terminal half-life values were estimated from two or three
time-points, corresponding to the antibiotic's elimination
phase.
Results
All rabbits developed empyema after the intrapleural
injection of turpentine and the inoculation with E. coli. In
all cases, and in accordance to previously reported data
[9] the estimated pleural fluid pH was < 7.10, while the
corresponding glucose levels were < 30 mg/dL (Table 1).
Linezolid
The mean (SD) linezolid concentration values for both
blood serum and pleural fluid samples (Cserum and Cpf,
respectively) corresponding to the sampling time inter-
vals (1, 2, 4, 6, 8 hours post administration) are shown in
Figure 1 and Table 2. The area under the concentration
versus time curve (AUC) was almost 4-fold higher in the
pleural fluid compared to the blood serum compartment.
The terminal half-life (T1/2) of linezolid was equal for the
two compartments, with a slight superiority for the T1/2
of the pleural fluid (Table 3). The time to equilibration
between the pleural fluid and blood serum compartments
seems to occur at 1.5 hours, with an onset of approxi-
mately 60% at the first hour compared to the correspond-
ing blood serum levels. The peak pleural fluid levels
(Cmaxpf of 2.02 ± 0.73 μg/ml) occurring 2 hours post
administration and decreasing slowly thereafter. With the
exception of samples collected at 1 hour (Cmaxserum of
2.10 ± 1.20 μg/ml versus Cmaxpf of 1.28 ± 1.60 μg/ml),
linezolid serum concentration values were significantly
lower from the corresponding pleural fluid ones (Stu-
dent's t-test, p < 0.05), during the 8 hours data collecting
period (Figure 1).
Ertapenem
The mean (SD) ertapenem concentration values for both
blood serum and pleural fluid samples (Cserum and Cpf,
respectively) corresponding to the sampling time inter-
vals (2, 8, 24, 48 and 72 hours post administration) are
shown in Figure 2 and Table 2. The area under the con-
centration versus time curve (AUC) and terminal half-life
(T1/2) of ertapenem was approximately one and half
higher in the pleural fluid compared to the blood serum
compartment (Table 3). Ertapenem penetrated into the
empyemic pleural fluid, exhibiting a similar onset and a
slightly lower decline compared to the corresponding
blood serum compartment (T1/2 serum = 1.03 vs T1/2 pf =
1.49). Equilibration between pleural fluid and blood
serum seems to occur at 1.5 hours after the ertapenem
administration, along with a concentration of 2.8 μg/ml.
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serum of 6.26 ± 2.98 μg/ml versus Cmaxpf of 3 ± 1.55 μg/
ml), ertapenem serum concentration values were signifi-
cantly lower than the corresponding pleural fluid ones
(Student's t-test, p < 0.05), during the 8 hours data col-
lecting period (Figure 2). There is a limitation of the
above estimations of the serum concentration of linezolid
because these made by only two time points measure-
ments.
Discussion
The present study shows that linezolid and ertapenem
penetrated well into empyemic pleural fluid. Significant
levels of both antibiotics remained in the pleural space for
up to 4 hours, despite diminishing blood antibiotic levels
over time. Specifically for ertapenem the elevated pleural
drug levels remained higher for the 8-hour period of our
study. These findings suggest that both antibiotics show
elevated concentrations and extended terminal half-life
time into the pleural cavity compared to the serum. These
facts, combined with the high extracellular distribution of
these antibiotics, suggest that they may be effective in the
treatment of pleural bacterial infection.
There are limited number of articles in the literature,
which have studied the correlation between the pleural
fluid and serum antibiotic levels. Teixeira et al [16] using
a rabbit model of empyema, determined the relationships
between the pleural fluid and serum antibiotic levels of
metronidazole, penicillin, clindamycin, ceftriaxone, van-
comycin and gentamicin. The pharmacokinetics of these
drugs were studied following intravenous administration.
It was found that the penetration of these antibiotics into
the infected pleural fluid and the equilibration between
the blood serum and pleural fluid varied substantially
between the various antibiotics. Liapakis et al studied the
relationship between the pleural fluid and blood serum
antibiotic levels of clarithromycin [17] levofloxacin and
moxifloxacin [18]. We used the same rabbit model and
protocol for detecting the relationship between linezolid
and ertapenem levels in blood serum and pleural fluid.
Linezolid is a novel oxazolidinone antimicrobial drug,
with an enhanced in vitro activity against Gram-positive
pathogens. It is a protein synthesis inhiditor [19] that
stops translation at the initiation step that involves the
binding of N-formylmethionyl-tRNA to the 70S ribosome
[20].
There are studies demonstrating its efficacy against
aortic valve endocarditis [21], staphylococcal endocardi-
tis [22] in patients with community-acquired and nosoco-
mial pneumonia [23], and its comparative efficacy versus
Table 2: Mean (± sd) concentrations (mcg/ml) of linezolid and ertapenem in blood serum (Cserum) and pleural fluid (Cpf) 
after the iv administration of a linezolid solution (10 mg/kg infused over a period) and an ertapenem solution (60 mg/kg 
infused over a period), to 10 and 8 New Zealand white rabbits, respectively
1 h 2 h 4 h 6 h 8 h
Linezolid
Cserum 2.10 ± 1.20 0.20 ± 0.28 < QL < QL < QL
N 10 10 9 7 7
Cpf 1.28 ± 1.60 2.02 ± 0.73* 1.70 ± 1.00 0.79 ± 0.85 0.16 ± 0.25
N 10 9 9 7 6
Ertapenem
Cserum 6.26 ± 2.98 2.80 ± 1.64 0.97 ± 1.09 0.79 ± 0.85 0.39 ± 0.25
N 8 8 8 7 6
Cpf 3.00 ± 1.55* 3.74 ± 1.39* 3.62 ± 1.40* 3.16 ± 1.20* 2.84 ± 0.90*
N 8 8 7 7 5
N = number of experimental animals, QL: estimations are lower than the analytical quantification limit. *: significantly different values from 
the corresponding pleural fluid ones (p < 0.05. student's t-test).
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intrapulmonary pharmacokinetics of the drug has been
thoroughly studied [26]. There is a case report for suc-
cessful treatment with linezolid of meningitis [27] and
data about its ability to penetrate into the cerebrospinal
fluid [28]. However, there are no studies on linezolid
pharmacokinetics into the pleural effusion. Our study
shows that linezolid penetrates in the pleural fluid exhib-
iting a 4-fold higher concentration level compared to the
blood serum compartment and an equal elimination half
- time (T1/2).
Ertapenem, a new carbapenem, demonstrates a broad
spectrum of in vitro activity against most Gram-negative
Table 3: The basic pharmacokinetic parameters of linezolid and ertapenem in pleural fluid and in blood serum after the 
i.v. infusion of linezolid solution (10 mg/kg) and of ertapenem solution (60 mg/kg) to 10 and 8 New Zealand white rabbits, 
respectively.
Blood serum Pleural fluid Rpf/ser
Linezolid
AUC 0-8 h (h.mcg/mL) 2.20 9.45 4.29
AUC 0-inf (h.mcg/mL) 2.24 9.72 4.34
T1/2 (hours) 0.98 1.18
Ertapenem
AUC 0-8 h (h.mcg/mL) 12.70 17.74 1.39
AUC 0-inf (h.mcg/mL) 12.77 18.76 1.47
T1/2 (hours) 1.03 1.49
AUC 0-8 h/0-inf : area under the linezolid/ertapenem concentration versus time curve corresponding to 0-8 hours 
and 0-inf time intervals, respectively. T1/2: terminal elimination half-life, of linezolid/ertapenem in pleural fluid and 
in blood serum. Rpf/ser : linezolid/ertapenem penetration ratio into the pleural fluid compared to blood serum.
Figure 1 Linezolid concentrations (mean ± sd, mcg/mL) in blood 
serum (circles) and pleural fluid (squares), in an experimental rab-
bit model of pleural empyema induced by inoculation with Es-
cherichia coli (ATCC 35218), after the i.v. administration of an 
linezolid solution (10 mg/kg) to 10 New Zealand white rabbits.
Figure 2 Ertapenem concentrations (mean ± sd, mcg/mL) in 
blood serum (circles) and pleural fluid (squares), in an experimen-
tal rabbit model of pleural empyema induced by inoculation with 
Esherichia coli (ATCC 35218), after the i.v. administration of an er-
tapenem solution (60 mg/kg) to 8 New Zealand white rabbits.
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nity-acquired and hospital-acquired infections [29].
Compared to other carbapenems it has a relatively long
half-life due to high protein binding capacity, permitting
once daily administration [30]. The in vitro activity of
ertapenem is retained against most isolates that produce
high-level AmpC βeta-lactamases (cephalosporinases)
and clavulanic-acid-inhibited extended-spectrum βeta-
lactamases [31]. There are several studies exhibiting its
efficacy in patients with complicated intra-abdominal
infections [32], urinary tract and pelvic infections [33],
and community-acquired pneumonia [34]. There is a
study concerning for the penetration of ertapenem into
the inflamed and non-inflamed meninges [35], while the
penetration in the pleural effusion has been studied for
the other antibiotic agents of the carbapenem family (imi-
penem, meropenem, panipenem and biapenem) [36]. In
this study, ertapenem penetrated well into the empyemic
pleural fluid, exhibiting a similar onset and a slightly
lower decline compared to the corresponding blood
serum compartment. The AUC values and the elimina-
tion half-time (T1/2) of ertapenem was approximately one
and half higher respectively in the pleural fluid compared
to the blood serum compartment. Based on literature
data that penetration of the meropenem in the pleural
fluid [37] which belongs into the same family with ertap-
enem and the penetration of ertapenem into cerebrospi-
nal fluid [36] we suggest that ertapenem may be effective
in the treatment of pleural effusion.
The equilibration between an antibiotic in the serum
and the pleural fluid depends on several factors. These
include the thickness of the pleura (equilibration will
occur less rapidly with a thicker pleura), the size of the
pleural effusion (equilibration will occur less rapidly with
larger pleural effusions), the degree of pleural inflamma-
tion (equilibration will occur more rapidly with inflam-
mation both due to increased protein flux; and the
infiltration of macrophages to the inflammatory area) and
the antibiotic itself {molecular weight, presence or
absence of liposolubility [38] and protein binding [39]}. In
our study, higher pleural fluid levels of linezolid and
ertapenem than serum levels were measured continu-
ously, after the first two hours of intravenous administra-
tion of both drugs. It is not clear if these results obtained
in the rabbit can be extrapolated exactly to humans, as
rabbits are a species with thin visceral pleura, while
humans have thick visceral pleura [40]. It is likely that the
equilibration of antibiotics would be more rapid in spe-
cies with thin pleura.
In conclusion, our data suggest that linezolid and ertap-
enem penetrated well into the epmyema pleural fluid,
achieving concentrations 2 to 3 fold higher than those in
the serum, for an extended period of time. Due to the
above mentioned differences of pleura anatomy between
rabbits and humans, in vivo studies are needed in patients
in order to evaluate the exact penetration characteristics
of these antibiotics into the human pleural fluid. A recent
study found that the combination of linezolid with ertap-
enem was associated with in vitro and in vivo highly syn-
ergistic antimicrobial activity [41]. Based on this, the
pharmacokinetic advantages of linezolid and ertapenem
in the pleural fluid make them as promising therapeutic
agents for parapneumonic pleural effusion, when they are
administered alone or in combination.
Authors' contributions and agreement
MS carried out the experimental protocol and collected
all the data. ST and GI contributed in the design of the
protocol, performed the statistical analysis, were involved
in the drafting of the manuscript and carried out the revi-
sions of the final version. MT and AT participated in the
design of the study, carried out the analytical procedures
and were involved in the drafting of the methodology of
the manuscript. IL and AP participated in the design and
the validation of the empyemic rabbit model. DB
designed the experimental protocol and gave the final
approval for the submission of this manuscript.
All authors read and approved the final manuscript.
This study was supported by a grant from Experimental
Research Center ELPEN A. E. Farma, Athens, Greece.
Competing interests
The authors declare that they have no competing interests.
Author Details
11st Pulmonary Clinic, General Hospital «G Papanikolaou», Thessaloniki, Greece
, 2Experimental & Research Center Elpen Pharmaceutical Co, Athens, Greece, 
3Department of Pneumonology, Medical School, Democritus University of 
Thrace, Alexandroupolis, Greece and 4Center of Toxicological Science and 
Research, Dept of Medicine, University of Crete, Heraklion, Greece
References
1. Bouros D: Parapneumonic Pleural Effusions and Empyema.  In Pleural 
Disease Edited by: Bouros D. New York, Marcel Dekker; 2004. 
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean 
NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney 
CG, Infectious Diseases Society of America; Infectious Diseases Society of 
America/American Thoracic Society: Consensus guidelines on the 
management of community-acquired pneumonia in adults.  Clin Infect 
Dis 2007, 44(Suppl 2):S27-72.
3. Sasse SA: Parapneumonic effusions and empyema.  Curr Opin Pulm Med 
1996, 2:520-526.
4. Strange C, Sahn SA: Management of parapneumonic pleural effusions 
and empyema.  Infect Dis Clin North Am 1991, 5:539-559.
5. Bouros D, Plataki M, Antoniou KM: Parapneumonic effusion and 
empyema: best therapeutic approach.  Monaldi Arch Chest Dis 2001, 
56:144-8.
6. Sasse S, Nguyen T, Mulligan M, Nai-San W, Mahutte K, Light RW: The 
effects of early chest tube placement on empyema resolution.  Chest 
1997, 111:1679-1683.
7. Liapakis IE, Kottakis I, Light RW, Bouros D: Pharmacokinetics and 
pharmacodynamics in the pleural space.  In Pleural Diseases Edited by: 
Bouros D. New York, Marcel Dekker; 2004:999-1008. 
Received: 8 April 2009 Accepted: 18 May 2010 
Published: 18 May 2010
This article is available from: http://www.journal-inflammation.com/content/7/1/22© 2010 Saroglou et al; licensee BioMed Cent al Ltd. is an Open Access articl  distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Infl mmation 2010, 7:22
Saroglou et al. Journal of Inflammation 2010, 7:22
http://www.journal-inflammation.com/content/7/1/22
Page 8 of 88. Hamm H, Light RW: Parapneumonic effusion and empyema.  Eur Respir J 
1997, 10:1150-1156.
9. Bouros D, Schiza S, Siafakas N: Utility of fibrinolytic agents for draining 
intrapleural infections.  Semin Respir Infect 1999, 14:39-47.
10. Sahn SA, Potts DE: Turpentine pleurisy in rabbits: a model of pleural 
fluid acidosis and low pleural fluid glucose.  Am Rev Respir Dis 1978, 
118:893-901.
11. Chandler TM, McCoskey EH, Byrd RP Jr, Roy TM: Comparison of the use 
and accuracy of methods for determining pleural fluid pH.  South Med J 
1999, 92:214-217.
12. Marel M, Stastny B, Melinova L, Svandova E, Light R: Diagnosis of pleural 
effusions. Experience with clinical studies, 1986 to 1990.  Chest 1995, 
107:1598-1603.
13. Peng GW, Stryd RP, Murata S, Igarashi M, Chiba K, Aoyama H, Aoyama M, 
Zenki T, Oza N: Determination of linezolid in plasma by reversed-phase 
high performance liquid chromatography.  Journal of Pharm Biomed 
Anal 1999, 20(1-2):65-73.
14. Soltani M, MacGowan A, Lovering A: Assay of ertapenem in human 
serum by high performance liquid chromatography.  Int J Antimicrobial 
Agents 27(2006):165-167.
15. Tobin CM, Sunderland J, White LO, MacGowa AP: A simple, isocratic high 
performance liquid chromatography assay for linezolid in human 
serum.  Journal of Antimicrobial Chemotherapy 2001, 48:605-608.
16. Teixeira LR, Sasse SA, Villarino MA, Nguyen T, Mulligan ME, Light RW: 
Antibiotic levels in empyemic pleural fluid.  Chest 2000, 117:1734-1739.
17. Liapakis IE, Light RW, Pitiakoudis MS, Karayiannakis AJ, Giamarellos-
Bourboulis , Ismailos G, Anagnostoulis S, Simopoulos CE, Bouros DE: 
Penetration of clarithromycin in experimental pleural empyema model 
fluid.  Respiration 2005, 72:296-300.
18. Liapakis IE, Kottakis I, Tzatzarakis MN, Tsatsakis AM, Pitiakoudis MS, 
Ypsilantis P, Light RW, Simopoulos CE, Bouros DE: Penetration of newer 
quinolones in the empyema fluid.  Eur Respir J 2004, 24:466-470.
19. Shinabarger D, Marotti K, Murray R, Lin A, Melchior E, Swaney S, Dunyak D, 
Demyan W, Buysse J: Mechanism of action of oxazolidinones: effects of 
linezolid and eperezolid on translation reactions.  Antimicrob Agents 
Chemother 1997, 41:2132-2136.
20. Swaney S, Aoki H, Ganoza M, Shinabarger D: The oxazolidinone linezolid 
inhibits initiation of protein synthesis in bacteria.  Antimicrob Agents 
Chemother 1998, 42:3251-3255.
21. Athanassopoulos G, Pefanis A, Sakka V, Liopoulos D, Perrea D, Giamarellou 
H: Linezolid in prophylaxis against experimental aortic valve 
endocartitis with enterococcus faecalis.  Antimicrob Agents Chemother 
2006, 50(2):654-7.
22. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL, Dailey CF, Ford CW, Batts 
DH, Gibson JK: Efficacy of linezolid in a staphylococcal endocarditis 
rabbit model.  J of Antimicr Chemother 2001, 47:349-352.
23. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH: Continuation of a 
randomized, double-blind, multicenter study of linezolid in patients 
with nosocomial pneumonia.  Clin Ther 2003, 25(3):980-92.
24. San Pedro GS, Cammarat SK, Oliphant TH, Todisco T: Linesolid versus 
ceftriaxone/cefpodoxime in patients hospitalized for the pneumonia.  
Scand J Infect Dis 2002, 34(10):720-8.
25. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH: 
Linezolid vs vancomysin: analysis of two double-blind studies of 
patients with aureus nosocomial pneumonia.  Chest 2003, 
124(5):1789-97.
26. Conte JE, Golden JA Jr, Kipps J, Zurlinden E: Intrapulmonary 
pharmacokinetics of linezolid.  Antimicrob Agents Chemother 2002, 
46(5):1475-1480.
27. Dinleyici EC, Yarar C, Dinleyici M, Yakut A: Successful treatment with 
linezolid of meningitis complicated with subdural empyema in a 6-
month-old boy.  J of Trop Pediatrics 2007, 53(6):431-433.
28. Boak LM, Li J, Spelman D, du Cros P, Nation RL, Rayner CR: Successful 
treatment and cerebrospinal fluid penetration of oral linezolid in a 
patient with coagulase-negative staphylococcus ventriculitis.  The 
Annals of Pharmacotherapy 2006, 40(7-8):1451-1455.
29. Livermore DM, Sefton AM: Properties and potential of ertapenem.  J 
Antimicrob Chemother 2003, 52:331-44.
30. Majumbar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry 
G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, 
Waldman S, Deutsch P, Rogers JD: Pharmacokinetics of ertapenem in 
healthy young volunteers.  Antimicrob Agents Chemother 2002, 
46:3506-11.
31. Jacoby G, Han P, Tran J: Comparative in vitro activities of carbapenem L-
749,345 and other antimicrobials against multiresistant gram-negative 
clinical pathogens.  Antimicrob Agents Chemother 1997, 41:1830-1.
32. Solomkin JS, Mazuski J: Intra-abdominal sepsis: newer interventional 
and antimicrobial therapies.  Infect Dis Clin North Am 2009, 
23(3):593-608.
33. Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, Woods GL, 
Teppler H: Ertapenem once a day versus piperacillin-tazobactam every 
6 hours for treatment of acute pelvic infections: A prospective, 
multicenter, randomized, double-blind study.  Infect Dis Obstet Gynecol 
2003, 11(1):27-37.
34. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A, 
Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group: 
A study evaluating the efficacy, safety, and tolerability of ertapenem 
versus ceftriaxone for the treatment of community-acquired 
pneumonia in adults.  Clin infect Dis 2002, 34:1076-1083.
35. Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Tauber MG: Activities of 
ertapenem, a New Long-Acting Carbapenem, against Penicillin-
Sensitive or -Resistant Pneumococci in Experimental Menigitis.  
Antimicrobial Agents and Chemotherapy 2003, 47(6):1943-1947.
36. Niwa T, Nakamura A, Kato T, Kutsuna T, Katou K, Morita H, Kojima Y, Itoh M: 
Pharmacokinetic study of pleural fluid penetration of carbapenem 
antibiotic agents in chemical pleurisy.  Respir Med 2006, 100(2):324-31.
37. Makino J, Kanke M, Nakashima E, Kamata M, Ozawa S, Maruyama H, 
Masuhara K, Kobayashi T: Pharmacokinetic study of penetration of 
meropenem into pleural effusion in patients with pleurisy.  Jpn J 
Antibiot 2002, 55(1):77-88.
38. Fraschini F, Nebuloni R, Cortelazzi R, Falchi M: Antibiotics and mucous 
membrane: pharmacokinetic aspects.  J Chemother 1991, 3(suppl 
1):182-9.
39. Wooddnutt G, Berry V, Mizen L: Effect of protein binding on penetration 
of β-lactams into rabbit peripheral lymph.  Antimicrob Agents Chemother 
1995, 39:2678-83.
40. Sakuma T, Kubo H, Tanita T, Koike K, Fujimura S: Penetration of 
intravenous antibiotics from the lung into the pleural space after 
pulmonary resection.  Thorac Cardiovasc Surg 1994, 107:955-957.
41. Jacqueline C, Caillon J, Grossi O, Le Mabecque V, Miegeville AF, Bugnon D, 
Batard E, Potel G: In vitro and in vivo assessment of linezolid combined 
with ertapenem: a highly synergistic combination against methicillin-
resistant Staphylococcus aureus.  Antimicrob Agents Chemother 2006, 
50(7):2547-9.
doi: 10.1186/1476-9255-7-22
Cite this article as: Saroglou et al., Pharmacokinetics of Linezolid and Ertap-
enem in experimental parapneumonic pleural effusion Journal of Inflamma-
tion 2010, 7:22
